No observations were issued issued to the company
Zydus Cadila said its wholly-owned subsidiary Alidac Pharmaceuticals has not received any observations from the US health regulator after inspection of its manufacturing facility located at SEZ, Ahmedabad.
“The US Food and Drug Administration (USFDA) inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals located at SEZ, Ahmedabad from May 28 to June 5, 2018. At the end of the inspection, no observation (483) is issued,” the company said in a BSE filing. The site manufactures oncology injectables for the regulated markets, it added.
- Advertisement -
Comments are closed.